GE HealthCare Technologies Inc. (GEHC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 18.46 means the share price is 18.46 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $29.0B is the value of all shares combined. Beta 1.30: the stock has moved about 30% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerGE HealthCare Technologies Inc. (GEHC) trades at $64.24 with MoonshotScore 59/100 (Grade B). GE HealthCare Technologies Inc. specializes in medical imaging, patient care solutions, and pharmaceutical diagnostics. Market cap: $29.0B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: May 10, 2026GEHC stock analysis for 2026: Analysts have set a consensus price target of $78.73 for GE HealthCare Technologies Inc., suggesting 22.6% upside from the current price of $64.24. The AI MoonshotScore is 59/100, in the Fair band (45-64) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
These figures come from statements filed 12 months ago — the most recent this company has published.
GEHC: 2/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Strongest side: Business Quality (8/10, Strong). Weakest side: Financial Safety (3/10, Weak).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
GE HealthCare Technologies Inc. (GEHC) Healthcare & Pipeline Overview
GE HealthCare Technologies Inc. delivers medical technology and digital solutions across imaging, ultrasound, patient care, and pharmaceutical diagnostics. With a global presence and a focus on precision health, GEHC addresses critical needs in diagnosis, treatment, and monitoring, operating with a P/E ratio of 18.46.
What Is the Investment Thesis for GEHC?
GE HealthCare presents a notable research candidate driven by its established market position, diverse product portfolio, and focus on innovation. The company's strong presence in medical imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics provides a stable revenue base with growth potential. With a profit margin of 7.5% and a gross margin of 42.5%, GEHC demonstrates solid profitability. Growth catalysts include the increasing demand for medical imaging and diagnostic services, driven by an aging global population and advancements in medical technology. The company's strategic focus on digital solutions and precision health further enhances its growth prospects. However, investors should be aware of potential risks such as intense competition, regulatory changes, and technological obsolescence. The company's beta of 1.30 indicates higher volatility compared to the market.
Based on FMP financials and quantitative analysis
GEHC Key Highlights
Market capitalization of $29.0B reflects GE HealthCare's significant presence in the medical technology sector.
- P/E ratio of 18.46 suggests a reasonable valuation relative to earnings.
- Gross margin of 42.5% indicates strong pricing power and efficient cost management.
- Dividend yield of 0.22% provides a modest income stream for investors.
- 53,000 employees worldwide demonstrate the company's extensive global operations and reach.
Who Are GEHC's Competitors?
GEHC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CAH Cardinal Health, Inc. | $236.76 | -1.35% | $55.5B | 875-pillar |
| ALC Alcon Inc. | $66.55 | -2.75% | $32.5B | 765-pillar |
| ONC BeOne Medicines Ltd. | $341.80 | -2.62% | $36.5B | 865-pillar |
| A Agilent Technologies, Inc. | $142.65 | -1.45% | $40.3B | 795-pillar |
| IQV IQVIA Holdings Inc. | $257.63 | +0.25% | $42.4B | 725-pillar |
| VEEV Veeva Systems Inc. | $263.67 | +1.10% | $42.8B | 905-pillar |
| BTSG BrightSpring Health Services, Inc. | $57.88 | -6.63% | $11.4B | 695-pillar |
| TEM Tempus AI, Inc. | $59.25 | -3.30% | $10.4B | 315-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GEHC's Key Strengths?
Diversified product portfolio across imaging, ultrasound, patient care, and diagnostics.
- Global presence and established distribution network.
- Strong brand reputation and customer relationships.
- Significant investment in research and development.
What Are GEHC's Weaknesses?
Exposure to regulatory changes and healthcare policy risks.
- Dependence on hospital capital spending budgets.
- Intense competition from other medical technology companies.
- Potential for product recalls or liability claims.
What Could Drive GEHC Stock Higher?
New product launches in medical imaging and digital health solutions.
- Expansion in emerging markets and strategic partnerships.
- Increasing demand for medical imaging and diagnostic services due to aging population.
- Continued investment in research and development to drive innovation.
What Are the Key Risks for GEHC?
Financial-distress signal — its Altman Z-Score of 1.66 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes and healthcare policy risks.
- Economic downturns and reduced healthcare spending.
- Intense competition from other medical technology companies.
- Cybersecurity threats and data breaches.
- Technological obsolescence and disruption from new entrants.
What Are the Growth Opportunities for GEHC?
- Expansion in Emerging Markets: GE HealthCare can capitalize on the growing demand for healthcare services in emerging markets such as China, India, and Brazil. These regions are experiencing rapid economic growth and increasing healthcare expenditure, creating significant opportunities for GEHC to expand its market presence and increase sales of its medical imaging and diagnostic products.
- Digital Health Solutions: GE HealthCare can leverage its expertise in medical technology to develop and offer innovative digital health solutions. This includes telemedicine platforms, remote patient monitoring systems, and AI-powered diagnostic tools. The digital health market is experiencing rapid growth, driven by the increasing adoption of telehealth and remote monitoring technologies. GEHC can capitalize on this trend by developing and offering cutting-edge digital health solutions that improve patient outcomes and reduce healthcare costs.
- Strategic Partnerships and Acquisitions: GE HealthCare can pursue strategic partnerships and acquisitions to expand its product portfolio and enter new markets. This includes partnering with other medical technology companies, healthcare providers, and research institutions to develop and commercialize innovative products and services. Acquisitions can also be used to acquire new technologies and capabilities, as well as to expand GEHC's geographic reach. The market for medical technology acquisitions is active, with numerous opportunities for GEHC to acquire complementary businesses and technologies.
- Focus on Precision Health: GE HealthCare can focus on developing and offering precision health solutions that are tailored to the individual needs of patients. This includes using genomic data, medical imaging, and other diagnostic information to develop personalized treatment plans. Precision health is a rapidly growing field, driven by the increasing availability of genomic data and the development of new diagnostic technologies. GEHC can capitalize on this trend by developing and offering precision health solutions that improve patient outcomes and reduce healthcare costs.
- Advancements in Artificial Intelligence (AI): GE HealthCare can integrate AI into its medical imaging and diagnostic products to improve their accuracy and efficiency. AI can be used to automate image analysis, detect anomalies, and provide decision support to healthcare professionals. The use of AI in medical imaging is growing rapidly, driven by the increasing availability of data and the development of new AI algorithms. GEHC can capitalize on this trend by integrating AI into its products and services, improving their value proposition and increasing their adoption.
What Are GEHC's Competitive Advantages?
- Strong brand reputation and established market position.
- Extensive product portfolio and global distribution network.
- Significant investment in research and development.
- Proprietary technology and intellectual property.
- High switching costs for customers due to the complexity and cost of medical equipment.
What Does GEHC Do?
GE HealthCare Technologies Inc., incorporated in 2022 and headquartered in Chicago, Illinois, is a global leader in medical technology, diagnostics, and digital solutions. Spun off from General Electric, the company builds on a legacy of innovation in healthcare. GE HealthCare operates through four primary segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers a range of technologies including molecular imaging, computed tomography (CT), magnetic resonance (MR), image-guided therapy, and X-ray systems, along with specialized products for women's health. The Ultrasound segment provides solutions for screening, diagnosis, and monitoring across various medical fields such as radiology, primary care, women's health, and cardiovascular applications. Patient Care Solutions focuses on providing medical devices, consumables, services, and digital solutions for patient monitoring, anesthesia delivery, respiratory care, diagnostic cardiology, and maternal-infant care. The Pharmaceutical Diagnostics segment develops and supplies diagnostic agents, including contrast media and molecular imaging agents, used in various imaging modalities. GE HealthCare's products and services are utilized in hospitals, clinics, and research institutions worldwide, supporting healthcare professionals in improving patient outcomes and enhancing the efficiency of healthcare delivery. The company's commitment to innovation and digital transformation positions it as a key player in the evolving healthcare landscape.
What Products and Services Does GEHC Offer?
- Develops and manufactures medical imaging equipment such as MRI, CT, and X-ray machines.
- Provides ultrasound systems for various medical applications.
- Offers patient monitoring and respiratory care solutions.
- Supplies diagnostic agents and contrast media for medical imaging.
- Provides digital solutions and software for healthcare providers.
- Offers services and support for its medical equipment.
How Does GEHC Make Money?
- Sells medical imaging equipment, ultrasound systems, and patient care solutions to hospitals, clinics, and other healthcare providers.
- Generates revenue from the sale of diagnostic agents and contrast media.
- Provides service and maintenance contracts for its equipment.
- Offers digital solutions and software subscriptions to healthcare providers.
What Industry Does GEHC Operate In?
GE HealthCare operates in the medical technology and healthcare information services industry, which is experiencing significant growth driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements. The competitive landscape includes major players like A: Agilent Technologies, Inc. and IQV: IQVIA Holdings Inc., as well as specialized companies focusing on specific segments of the market. GE HealthCare's broad product portfolio and global presence position it as a key competitor in this dynamic industry.
Who Are GEHC's Key Customers?
- Hospitals and clinics
- Diagnostic imaging centers
- Research institutions
- Government healthcare agencies
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 100% of our measures
- ● Price is current
- ● Latest filing 44 days ago
- ● Covered by analysts
Why 59?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.43 Return on equity (Business Quality)
- +0.27 Financial-health checklist (Financial Strength)
- +0.27 Gross profit per dollar of assets (Business Quality)
What is holding it back
- -0.60 Debt to equity (Financial Strength)
- -0.48 5-year net income per share (Growth)
- -0.27 Net debt vs earnings (Financial Strength)
Risk penalties applied
- -0.03 Bankruptcy-risk score in the grey zone
- -0.06 Reported profit not backed by cash flow
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 61 |
| 2026-08-26 | 61 |
| 2026-08-29 | 61 |
| 2026-09-01 | 61 |
| 2026-09-04 | 60 |
| 2026-09-07 | 59 |
| 2026-09-10 | 59 |
What changed?
The grade moved from 61 to 59 (-2).
What moved it up or down:
- -8 Valuation
- -6 Momentum
- -1 Financial Strength
Held back by:
- +2 Growth
- +1 Business Quality
Over the same 18 days the stock moved -12.9%.
GE HealthCare Technologies Inc. Financial Trajectory
GE HealthCare Technologies Inc. (GEHC) reported $5.29B in revenue for Q2 FY2026, reflecting 3.2% growth compared to the prior quarter. The company recorded net income of $573.0M, with diluted EPS of $1.26. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, GEHC averaged $0.87 in diluted EPS.
Company Profile
GE HealthCare Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Peter J. Arduini. GEHC has traded publicly since 2022.
How GE HealthCare Technologies Inc. Is Valued
GE HealthCare Technologies Inc. carries a market capitalization of $29.0B, placing it in the large-cap category. Analyst price targets span from $65.00 to $90.00, with a consensus of $78.73. At the current price of $64.24, that implies approximately 23% upside potential. Relative to its peer group, GEHC's quantitative score of 59/100 is below the peer average of 74/100.
Key Financial Metrics
Return on equity for GE HealthCare Technologies Inc. stands at 14.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.1%, showing how much profit it generates from its asset base. GEHC trades at a trailing price-to-earnings ratio of 18.46, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
GE HealthCare Technologies Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.66 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
GE HealthCare Technologies Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.3% above estimates on average.
Insider Activity
Over the past six months, GE HealthCare Technologies Inc. insiders filed 40 SEC Form 4 transactions — 21 sales and 19 purchases. On net that is roughly 115K shares acquired (about $3.7M) — insiders putting money in tends to read as conviction.
GEHC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio across imaging, ultrasound, patient care, and diagnostics.
- Global presence and established distribution network.
- Strong brand reputation and customer relationships.
- Significant investment in research and development.
Bear Case
- Exposure to regulatory changes and healthcare policy risks.
- Dependence on hospital capital spending budgets.
- Intense competition from other medical technology companies.
- Potential for product recalls or liability claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026
From the Earnings Call
“In PDx, we had a strong quarter in contrast media and robust growth in U.S. radiopharmaceuticals. Additionally, we are on track with our Flyrcado ramp. In the quarter, we delivered 545 doses for the week ending July 24. This is approximately a 40% increase over April levels. We remain confident in our medium-term target of $500 million or more in annual revenues by 2028.”
— Peter Arduini, President and CEO
“We're maintaining full year guidance, and this reflects 3% to 4% organic sales growth and 10 to 40 basis points adjusted EBIT margin expansion that gets us to a range of 15.4% to 15.7%. We're maintaining our adjusted EPS guidance in the range of $4.80 to $5.”
— Peter Arduini, President and CEO
GEHC Q2 FY2026 earnings call transcript · 2026-07-29
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $5.29B | $573M | $1.26 |
| Q1 FY2026 | $5.13B | $389M | $0.85 |
| Q4 FY2025 | $4.67B | $184M | $0.40 |
| Q3 FY2025 | $5.14B | $446M | $0.98 |
Q2 FY2026 · filed 29 Jul 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
GEHC Latest News
-
TransMedics Names Fernando Araujo as CFO; Maintains 2026 Revenue Outlook
MT Newswires · Sep 10, 2026
-
GE HealthCare Technologies Inc. (GEHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
seekingalpha.com · Sep 9, 2026
-
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
zacks.com · Sep 9, 2026
-
Vaso Gains More Than 65% in Three Months: What's Driving the Stock?
Yahoo! Finance: GEHC News · Sep 8, 2026
GEHC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for GEHC.
Price Targets
Median: $80.00 (+22.6% from current price)
Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice
GEHC MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. GEHC scores 59/100 (Grade B): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
TransMedics Names Fernando Araujo as CFO; Maintains 2026 Revenue Outlook
GE HealthCare Technologies Inc. (GEHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
Vaso Gains More Than 65% in Three Months: What's Driving the Stock?
Latest GE HealthCare Technologies Inc. Analysis
Leadership: Peter J. Arduini
CEO
Peter J. Arduini is the President and Chief Executive Officer of GE HealthCare. Prior to this role, he served as President and CEO of Integra LifeSciences, a global leader in regenerative medicine. He has held various leadership positions at Baxter Healthcare and Johnson & Johnson. Arduini holds a Bachelor of Science degree in Marketing from Loyola University and a Master of Business Administration degree from Northwestern University's Kellogg School of Management. His extensive experience in the medical device and healthcare industries makes him well-suited to lead GE HealthCare.
Track Record: Since becoming CEO of GE HealthCare, Peter Arduini has focused on driving innovation, expanding the company's digital health offerings, and improving operational efficiency. He has overseen the successful spin-off of GE HealthCare from General Electric and has set a strategic vision for the company's future growth. Under his leadership, GE HealthCare has continued to invest in research and development and has launched several new products and services.
What Investors Ask About GE HealthCare Technologies Inc. (GEHC) — Healthcare
What does the AI Score mean for GEHC?
GEHC holds an AI Score of 59/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. GE HealthCare Technologies Inc. specializes in medical imaging, patient care solutions, and pharmaceutical diagnostics.
Is GEHC a good stock?
Stock Expert AI does not rate GEHC buy, sell or hold. GE HealthCare Technologies Inc. carries a MoonshotScore of 59/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for GEHC?
The main risks for GEHC include regulatory changes and healthcare policy risks, which could impact the demand for its products and services.
What are the key factors to evaluate for GEHC?
GE HealthCare Technologies Inc. (GEHC) holds an AI score of 59/100 (moderate). P/E: 18.46x vs the S&P 500's ~20-25x. Analysts target $78.73 (+23%). Not financial advice.
How frequently does GEHC data refresh on this page?
GEHC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GEHC's recent stock price performance?
GE HealthCare Technologies Inc. (GEHC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across imaging, ultrasound, patient care, and diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GEHC overvalued or undervalued right now?
GE HealthCare Technologies Inc. (GEHC) trades at 18.46x earnings. Analysts target $78.73 (+23%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of GEHC?
Yes, most major brokerages offer fractional shares of GE HealthCare Technologies Inc. (GEHC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GEHC's earnings and financial reports?
GE HealthCare Technologies Inc. (GEHC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for GEHC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of 2026-05-10.